Will covid-19 vaccines save lives? Current trials aren’t designed to tell us

  title={Will covid-19 vaccines save lives? Current trials aren’t designed to tell us},
  author={Peter Doshi},
The world has bet the farm on vaccines as the solution to the pandemic, but the trials are not focused on answering the questions many might assume they are. Peter Doshi reports 
Covid-19 vaccines: In the rush for regulatory approval, do we need more data?
After rollout under emergency authorisation, manufacturers of covid-19 vaccines now have their sights on regulatory approval. But what’s the rush, asks Peter Doshi, and is just six months of data
Covid-19: Sputnik vaccine rockets, thanks to Lancet boost
Chris van Tulleken argues that peer review is inadequate to decide the risk-benefit ratio of new drugs.
Vaccines, therapeutics, and diagnostics for covid-19: redesigning systems to improve pandemic response
Rohit Ramchandani and colleagues propose a framework to ensure essential public health tools are fairly distributed in future pandemics
COVID-19 research and non-vaccine treatment
Geroge Winter discusses the recent research that has been carried out on COVID-19, why not all of it is up to standard and why it warrants further critique and development
Covid-19 vaccines and treatments: we must have raw data, now
Data should be fully and immediately available for public scrutiny to improve the quality and transparency of public information in the energy sector.
Vaccination hesitancy and the “myth” on mRNA‐based vaccines in Italy in the COVID‐19 era: Does urgency meet major safety criteria?
This commentary has tried to elucidate issues about vaccine efficacy, vaccine‐borne adverse effects and vaccine clinical trial studies in COVID‐19 pandemic.
SARS-CoV-2 vaccines, where do we stand?
Vaccination against the SARS-CoV-2, the virus responsible for the Covid-19 pandemic, represents a major infection control strategy in the absence of effective treatment of the disease to date.
Covid-19 vaccine trial protocols released
A rare opportunity for public scrutiny of these key trials for the first time is offered in the UK.


Pandemrix vaccine: why was the public not told of early warning signs?
  • P. Doshi
  • Medicine
    British Medical Journal
  • 2018
Eight years after the pandemic influenza outbreak, a lawsuit alleging that GlaxoSmithKline’s Pandemrix vaccine caused narcolepsy has unearthed internal reports suggesting problems with the vaccine’s
Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency.
Regulatory review of the numerous coronavirus disease 2019 (COVID-19) vaccine candidates will occur under intense clinical, economic, and political pressure, with the FDA established its expectation that an approved vaccine would reduce the occurrence or severity of disease in at least 50% of recipients, but that criterion could change.
The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial.
In the elderly, influenza vaccination may halve the incidence of serological and clinical influenza (in periods of antigenic drift), which is less pronounced for self-reported influenza.
Coronavirus Disease 2019–COVID-19
Analysis of epidemiological, diagnostic, clinical, and therapeutic aspects, including perspectives of vaccines and preventive measures that have already been globally recommended to counter this pandemic virus, suggest that this novel virus has been transferred from an animal source, such as bats.
Impact of influenza vaccination on seasonal mortality in the US elderly population.
The decline in influenza-related mortality among people aged 65 to 74 years in the decade after the 1968 pandemic is attributed to the acquisition of immunity to the emerging A(H3N2) virus, and observational studies substantially overestimate vaccination benefit.